These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 31534348)
1. lncRNA Ge P; Cao L; Yao YJ; Jing RJ; Wang W; Li HJ Onco Targets Ther; 2019; 12():6105-6117. PubMed ID: 31534348 [No Abstract] [Full Text] [Related]
2. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs). Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523 [TBL] [Abstract][Full Text] [Related]
3. Suppression of ZNF205-AS1/EGR4 positive feedback loop attenuates cisplatin resistance of non-small cell lung cancer cells via targeting miR-138-5p/OCT4 pathway. Li H; Jin Y; Zhu Y; Shen B; Xu Y J Thorac Dis; 2024 Jan; 16(1):296-310. PubMed ID: 38410545 [TBL] [Abstract][Full Text] [Related]
4. Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer. Chang F; Li J; Sun Q; Wei S; Song Y Bioengineered; 2022 Apr; 13(4):8806-8822. PubMed ID: 35287543 [TBL] [Abstract][Full Text] [Related]
5. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis. Xie H; Yao J; Wang Y; Ni B Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477 [TBL] [Abstract][Full Text] [Related]
6. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of Long Non-Coding RNA Zhan Y; Abuduwaili K; Wang X; Shen Y; Nuerlan S; Liu C Cancer Manag Res; 2020; 12():7725-7737. PubMed ID: 32943921 [TBL] [Abstract][Full Text] [Related]
8. LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis. Zeng Z; Zhao G; Zhu H; Nie L; He L; Liu J; Li R; Xiao S; Hua G Cancer Cell Int; 2020; 20():350. PubMed ID: 32742197 [TBL] [Abstract][Full Text] [Related]
9. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis. Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110 [TBL] [Abstract][Full Text] [Related]
10. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Cai Y; Dong ZY; Wang JY Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323 [TBL] [Abstract][Full Text] [Related]
11. FoxD2-AS1 promotes glioma progression by regulating miR-185-5P/HMGA2 axis and PI3K/AKT signaling pathway. Ni W; Xia Y; Bi Y; Wen F; Hu D; Luo L Aging (Albany NY); 2019 Mar; 11(5):1427-1439. PubMed ID: 30860979 [TBL] [Abstract][Full Text] [Related]
12. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Fu J; Cai H; Wu Y; Fang S; Wang D Gene; 2020 Sep; 755():144886. PubMed ID: 32534055 [TBL] [Abstract][Full Text] [Related]
13. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression. Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022 [TBL] [Abstract][Full Text] [Related]
14. circHUWE1 Exerts an Oncogenic Role in Inducing DDP-Resistant NSCLC Progression Depending on the Regulation of miR-34a-5p/TNFAIP8. Yang X; Sun Q; Song Y; Li W Int J Genomics; 2021; 2021():3997045. PubMed ID: 34901263 [TBL] [Abstract][Full Text] [Related]
15. Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis. Gu N; Wang X; Di Z; Xiong J; Ma Y; Yan Y; Qian Y; Zhang Q; Yu J Aging (Albany NY); 2019 Nov; 11(22):10266-10283. PubMed ID: 31770107 [TBL] [Abstract][Full Text] [Related]
16. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Xiao XH; He SY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431 [TBL] [Abstract][Full Text] [Related]
17. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition. Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351 [TBL] [Abstract][Full Text] [Related]
18. miR-96-5p regulates cervical cancer cell resistance to cisplatin by inhibiting lncRNA TRIM52-AS1 and promoting IGF2BP2. Wu EY; Huang LP; Bao JH Kaohsiung J Med Sci; 2022 Dec; 38(12):1178-1189. PubMed ID: 36354205 [TBL] [Abstract][Full Text] [Related]
19. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948 [TBL] [Abstract][Full Text] [Related]
20. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2. Liu Y; Zhang Y; Li Q; Xu R; Huang N Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]